Nebojša Stanković

发表

Development of a long acting human growth hormone analog suitable for once a week dosing.

Danielle E. Dettling, Mark Horn, F. Brunel, 2013, Bioorganic & medicinal chemistry letters.

Development of an Effective Palladium Removal Process for VEGF Oncology Candidate AG13736 and a Simple, Efficient Screening Technique for Scavenger Reagent Identification

Shu Yu, N. Sach, S. A. O'neill-slawecki, 2008 .

5,6-Dihydro-1H-pyridin-2-ones as potent inhibitors of HCV NS5B polymerase.

Yuefen Zhou, S. Webber, D. Murphy, 2009, Bioorganic & medicinal chemistry letters.

Efficient synthesis of 2,6-disubstituted-5-hydroxy-3-oxo-2,3-dihydro-pyridazine-4-carboxylic acid ethyl esters

Yuefen Zhou, D. Murphy, Lian-Sheng Li, 2008 .

Process development and scale-up of AG035029

Nebojsa Stankovic, Mark B. Mitchell, Shu Yu, 2007 .

Development of a Scalable Synthesis to VEGFR Inhibitor AG-28262

Sean Neville, R. Scott, Nebojša Stanković, 2006 .

Parallel synthesis and screening of peptide conjugates.

A. Bhat, A. Dirksen, M. J. Matin, 2014, Bioconjugate chemistry.

Synthesis of New Pyridazinone Derivatives: 2,6-Disubstituted 5-Hydroxy-3(2H)-pyridazinone-4-carboxylic Acid Ethyl Esters

Yuefen Zhou, S. Webber, D. Murphy, 2007 .

Development of novel linkers to conjugate pharmacophores to a carrier antibody.

B. Liu, A. Bhat, R. Lappe, 2012, Bioorganic & medicinal chemistry letters.

Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 3: Further optimization of the 2-, 6-, and 7'-substituents and initial pharmacokinetic assessments.

C. Kissinger, Qiang Zhao, Yuefen Zhou, 2008, Bioorganic & medicinal chemistry letters.

Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones: Part 4. Optimization of DMPK properties.

Matthew A. Lardy, Yuefen Zhou, S. Webber, 2008, Bioorganic & medicinal chemistry letters.